Table 1:
Baseline Characteristics of Liver Transplant Recipients Stratified Using Recipients Diabetes
| With Diabetes | Without Diabetes | ||
|---|---|---|---|
| Recipient Variables | n = 6324 (43.39 %) | n = 8251 (56.61 %) | p-value |
|
| |||
| Recipient Demographics | |||
| Age, mean ± SD, y | 58.50 (8.31) | 54.50 (11.10) | < 0.001 |
| Male sex, n (%) | 58.10 (%) | 56.90 (%) | 0.170 |
| Race, n (%) | < 0.001 | ||
| White | 77.90 (%) | 78.60 (%) | |
| Black | 3.62 (%) | 5.16 (%) | |
| Hispanic | 14.70 (%) | 12.80 (%) | |
| Asian | 2.36 (%) | 2.17 (%) | |
| Other | 1.44 (%) | 1.31 (%) | |
| BMI, mean ± SD, kg/m2 | 31.10 (5.99) | 29.70 (6.39) | < 0.001 |
| Comorbidities | |||
|
| |||
| Hepatitis B, n (%) | 4.06 (%) | 5.47 (%) | |
| Hepatitis C, n (%) | 14.50 (%) | 15.00 (%) | |
| Alcoholic Liver Disease, n (%) | 27.00 (%) | 33.90 (%) | |
| Hepatic Variables | |||
|
| |||
| Ascites, n (%) | 0.750 | ||
| Absent | 14.00 (%) | 13.80 (%) | |
| Slight | 47.20 (%) | 47.80 (%) | |
| Moderate | 38.80 (%) | 38.30 (%) | |
| Encephalopathy, n (%) | 0.400 | ||
| None | 24.50 (%) | 25.30 (%) | |
| 1–2 | 62.20 (%) | 61.20 (%) | |
| 3–4 | 13.30 (%) | 13.50 (%) | |
| TIPS Procedure, n (%) | 14.20 (%) | 9.73 (%) | < 0.001 |
| MELD Scores, mean ± SD | 22.90 (8.84) | 24.90 (8.96) | < 0.001 |
| Immunosuppressants | |||
|
| |||
| Mycophenolate Mofetil, n (%) | 82.00 (%) | 81.50 (%) | 0.460 |
| Cyclosporine, n (%) | 5.30 (%) | 4.79 (%) | 0.170 |
| Tacrolimus, n (%) | 90.00 (%) | 90.60 (%) | 0.200 |
| Sirolimus, n (%) | 2.02 (%) | 1.62 (%) | 0.082 |
| Steroids, n (%) | 90.70 (%) | 91.20 (%) | 0.370 |
| Laboratory Markers | |||
|
| |||
| Albumin (mg/dL) | 3.07 (0.71) | 3.03 (0.73) | < 0.001 |
| Creatinine (mg/dL) | 1.65 (1.13) | 1.54 (1.09) | < 0.001 |
| INR | 1.93 (0.86) | 2.18 (1.21) | < 0.001 |
| Total Bilirubin (mg/dL) | 8.30 (10.50) | 10.90 (11.30) | < 0.001 |
| Critical Care and Life Support | |||
|
| |||
| Artificial liver devices, n (%) | 0.03 (%) | 0.05 (%) | 0.700 |
| Primary inotropic agent, n (%) | 0.770 | ||
| dobutamine, n (%) | 2.10 (%) | 2.11 (%) | |
| dopamine, n (%) | 16.20 (%) | 16.30 (%) | |
| epinephrine, n (%) | 0.89 (%) | 1.12 (%) | |
| levophed, n (%) | 16.50 (%) | 16.00 (%) | |
| neosynephrine, n (%) | 15.90 (%) | 15.60 (%) | |
| none, n (%) | 46.10 (%) | 46.60 (%) | |
| other, n (%) | 2.29 (%) | 2.13 (%) | |
| Secondary inotropic agent, n (%) | 0.980 | ||
| dobutamine, n (%) | 0.49 (%) | 0.56 (%) | |
| dopamine, n (%) | 1.11 (%) | 1.09 (%) | |
| epinephrine, n (%) | 0.54 (%) | 0.64 (%) | |
| levophed, n (%) | 3.38 (%) | 3.35 (%) | |
| neosynephrine, n (%) | 4.78 (%) | 4.78 (%) | |
| none, n (%) | 88.10 (%) | 87.90 (%) | |
| other, n (%) | 1.64 (%) | 1.73 (%) | |
| Ternary inotropic agent, n (%) | 0.440 | ||
| dobutamine, n (%) | 0.16 (%) | 0.16 (%) | |
| dopamine, n (%) | 0.06 (%) | 0.08 (%) | |
| epinephrine, n (%) | 0.24 (%) | 0.11 (%) | |
| levophed, n (%) | 0.47 (%) | 0.39 (%) | |
| neosynephrine, n (%) | 0.51 (%) | 0.51 (%) | |
| none, n (%) | 98.20 (%) | 98.20 (%) | |
| other, n (%) | 0.38 (%) | 0.52 (%) | |
| ICU admission, n (%) | 13.93 (%) | 17.28 (%) | |
| Ventilator Support, n (%) | 4.63 (%) | 6.53 (%) | < 0.001 |
| Donor Demographics | |||
|
| |||
| Donor Age, mean ± SD, y | 44.20 (17.30) | 42.80 (16.90) | < 0.001 |
| Donor Male sex, n (%) | 59.30 (%) | 58.90 (%) | 0.630 |
| Donor Race, n (%) | 0.230 | ||
| White | 65.40 (%) | 65.40 (%) | |
| Black | 18.90 (%) | 18.50 (%) | |
| Hispanic | 11.20 (%) | 12.00 (%) | |
| Asian | 2.26 (%) | 2.33 (%) | |
| Other | 2.18 (%) | 1.78 (%) | |
| Donor BMI, mean ± SD, kg/m2 | 28.30 (6.88) | 28.00 (6.56) | 0.037 |
| Donor Laboratory Markers | |||
|
| |||
| Donor Creatinine, mean ± SD, mg/dL | 1.72 (1.78) | 1.70 (1.79) | 0.240 |
| Donor Total Bilirubin, mean ± SD, mg/dL | 0.91 (0.94) | 0.90 (0.86) | 0.770 |
‡
Assistance variable was created through combining the multileveled activity and functional status scales into three dependence categories.